Four insights:
1. Mr. LeDuc is replacing Brent Norton, MD, who will remain on the board of directors.
2. Mr. LeDuc has 32 years of experience operating in senior executive roles with medical device and biopharma companies and 22 years working in the musculoskeletal market.
3. He has worked in senior roles at Inception Therapeutics, Genzyme, Biomatrix, Serono and BioSyntech.
4. Ortho RTi is preparing for its first human trial to test its biopolymer, Ortho-R, for the treatment of rotator cuff injuries.
“I am excited to be joining the Ortho RTi team at this critical time in the development of its Ortho-R program,” said Mr. LeDuc. “The potential to develop Ortho RTi’s proprietary biopolymer as a revolutionary platform for the treatment of any type of soft-tissues injuries is at our reach.”
More articles on biologics:
Minnesota seeks to expand stem cell research through state initiative — 4 insights
Stem cell controversies — Where we are in 2019
4 key updates in biologics for spine
